Comparative Pharmacology
Head-to-head clinical analysis: DIFICID versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFICID versus XERAVA.
DIFICID vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
200 mg (tablet) orally twice daily for 10 days.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category C
Category C
Antibiotic
Antibiotic